Figure 3.
Administration of low-dose cyclophosphamide (CP) in combination with oncolytic adenoviruses did not impair antitumor and anti-adenovirus T-cell response. Interferon-γ (IFN-γ) ELISPOT analysis was performed on patients before and after treatment. (a) Adenovirus only (Ad); (b) Ad + metronomic CP per os; (c) Ad + CP single intravenous administration; (d) Ad + metronomic CP per os + single intravenous (i.v.) administration. SFU, spot forming units.